Imaging the Folate Receptor on Cancer Cells with 99mTc-Etarfolatide: Properties, Clinical Use, and Future Potential of Folate Receptor Imaging
Imaging the Folate Receptor on Cancer Cells with 99mTc-Etarfolatide: Properties, Clinical Use, and Future Potential of Folate Receptor Imaging
复制标题
DOI：
10.2967/jnumed.113.133074
复制
发表时间：
2014-05-01
影响因子：
9.3
通讯作者：
Weber, Wolfgang A.
中科院分区：
文献类型：
--
作者：
Maurer, Alan H.;Elsinga, Philip;Weber, Wolfgang A.
叶酸受体（FR）在卵巢癌、非小细胞肺癌、子宫内膜癌、乳腺癌等上皮性肿瘤中均有表达，因此可作为治疗靶点。评估肿瘤中的FR表达可能有助于识别可以从FR靶向治疗（如vintafolide和farletuzumab）中获益的患者。存在不同的方法来检测FR表达。组织取样具有有限的临床效用，主要是因为它需要侵入性程序。Tc-99 m-etarfollide是一种Tc-99 m标记的叶酸结合物，在欧洲和美国处于后期试验阶段。它允许非侵入性的，全身成像的FR。这篇评论的重点是FR成像剂，以及它如何可能被用来指导FR靶向治疗。
Folate receptor (FR) can be used as a therapeutic target because of its expression on different epithelial cancers, such as ovarian, non-small cell lung, endometrial, and breast cancer. Assessing FR expression in tumors may help to identify patients who can benefit from FR-targeted therapeutics, such as vintafolide and farletuzumab. Different methods exist to detect FR expression. Tissue sampling has limited clinical utility, mainly because it requires an invasive procedure. Tc-99m-etarfolatide, a Tc-99m-labeled folate conjugate, is in latephase trials in Europe and the United States. It allows noninvasive, whole-body imaging of the FR. This review focuses on this FR-imaging agent and how it may be used to direct FR-targeted therapy.